Myelogenous Leukemia, Acute Clinical Trial
Official title:
A Phase II Study of Iressa (Gefitinib), in Patients With Relapsed or Refractory Acute Myelogenous Leukemia and in Older Patients With Newly Diagnosed Acute Myelogenous Leukemia
The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
Patients will receive Iressa daily until either disease progression or intolerable toxicity
develops. On Day 1 of treatment, a physical exam and bloodwork will be performed. Once
weekly for the first 8 weeks, a physical exam and complete blood count with differential
will be performed.
For the first year, a physical exam, bloodwork will be performed monthly. Bone marrow
biopsies will be performed after the first month of therapy and then every 3 months for the
first year. After the first year a physical exam, bloodwork will be performed every 3 months
and bone marrow biopsies every 6 months.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00374296 -
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02665065 -
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 3 | |
| Terminated |
NCT00907517 -
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
|
Phase 1 | |
| Completed |
NCT01635296 -
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01773408 -
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01641250 -
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
|
Phase 1 | |
| Recruiting |
NCT04989335 -
Bisantrene Combination for Resistant AML
|
Phase 2 |